المؤلفون: M. A. Borisova, G. V. Lukina, Ya. A. Sigidin, E. L. Luchikhina, D. E. Karateev, A. A. Novikov, E. N. Aleksandrova, M. V. Cherkasova, E. S. Aronova, S. L. Glukhova, E. L. Nasonov, М. А. Борисова, Г. В. Лукина, Я. А. Сигидин, Е. Л. Лучихина, Д. Е. Каратеев, А. А. Новиков, Е. Н. Александрова, М. В. Черкасова, Е. С. Аронова, С. И. Глухова, Е. Л. Насонов

المصدر: Rheumatology Science and Practice; Vol 55, No 4 (2017); 368-375 ; Научно-практическая ревматология; Vol 55, No 4 (2017); 368-375 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20174

مصطلحات موضوعية: предикторы эффективности терапии, rheumatoid arthritis, biological therapy, cytokines, predictors of the effectiveness of therapy, ревматоидный артрит, биологическая терапия, цитокины

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2409/1597; Александрова ЕН, Насонов ЕЛ. Иммунопатология ревматоидного артрита. В кн.: Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. С. 19- 21 [Aleksandrova EN, Nasonov EL. Immunopathology of rheumatoid arthritis. In: Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological preparations in treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013. P. 19-21].; Alex P, Szodoray P, Knowlton N, et al. Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin Exp Rheumatol. 2007 Jul-Aug;25(4):584-92.; Новиков АА. Многопараметрический анализ лабораторных биомаркеров в диагностике ревматоидного артрита. Дисс. … докт. биол. наук. Москва; 2014. С. 6-14 [Novikov AA. Mnogoparametricheskii analiz laboratornih biomarkerov v diagnostike revmathoidnogo artrita. Diss. . dokt. biоl. nauk [Multiparameter analysis of laboratory biomarkers in the diagnosis of rheumatoid arthritis]. Moscow; 2014. P. 6-14].; Umemura M, Isozaki T, Ishii S, et. al. Reduction of Serum ADAM17 Level Accompanied with Decreased Cytokines after Abatacept Therapy in Patients with Rheumatoid Arthritis. Int J Biomed Sci. 2014 Dec;10(4):229-35.; Насонов ЕЛ. Абатацепт. В кн.: Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. С. 221 [Nasonov EL. Abatacept. In: Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological preparations in treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013. P. 221].; Korhonen R, Moilanen E. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009 Apr;104(4):276-84. doi:10.1111/j.1742-7843.2009.00375.x; Moreland LW, Alten R, van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dosefinding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002 Jun;46(6):1470-9. doi:10.1002/art.10294; Kremer JM, Genant HK, Moreland LW, et al. Results of a twoyear follow up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008 Apr; 58(4):953-63. doi:10.1002/art.23397; Schiff M, Keiserman M, Codding C, et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open- label extension of the ATTEST Study. Ann Rheum Dis. 2011 Nov;70(11):2003-7. doi:10.1136/annrheumdis-2011-200316; Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med. 2005;353:1114-23. doi:10.1056/NEJMoa050524; Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs. A one-year randomized, placebo-controlled study. Arthritis Rheum. 2006 Sep;54(9):2807-16. doi:10.1002/art.22070; Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009 Nov;68(11):1708-14. doi:10.1136/ard.2008.099218; Wells AF, Westhovens R, Reed DM, et al. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. J Rheumatol. 2011 Nov;38(11):2362-8. doi:10.3899/jrheum.110054; Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated infl ammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010 Mar;69(3):510-6. doi:10.1136/ard.2009.119016; Nü βlein HG, Alten R, Galeazzi M, et al. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2- year, observational, prospective ACTION study. BMC Musculoskelet Disord. 2014 Jan 11;15:14. doi:10.1186/1471-2474-15-14; Лукина ГВ, Сигидин ЯА, Мазуров ВИ и др. Предварительные результаты применения абатацепта в клинической практике. В кн.: Насонов ЕЛ, редактор. Генно- инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. С. 386- 387 [Lukina GV, Sigidin IA, Mazurov VI, et al. Preliminary results of abatacept treatment in routine practice. In: Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological preparations in treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013. P. 386-387].; Борисова МА, Лукина ГВ, Сигидин ЯА и др. Сравнительная оценка эффективности и безопасности абатацепта у пациентов с разной длительностью ревматоидного артрита. Научно-практическая ревматология. 2016;54(6):667-73 [Borisova MA, Lukina GV, Sigidin YaA, et al. Comparative evaluation of the efficacy and safety of abatacept in patients with different duration of rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(6):667-73 (In Russ.)]. doi:10.14412/1995-4484- 2016-667-673; Weisman M, Durez P, Hallegua D, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol. 2006;33(11):2162-6.; Umemura M, Isozaki T, Ishii S, et al. Reduction of serum ADAM17 level accompanied with decreased cytokines after abatacept therapy in patients with rheumatoid arthritis. Int J Biomed Sci: IJBS. 2014;10(4):229-35.; Pieper J, Herrath J, Raghavan S, et al. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol. 2013;14:34. doi:10.1186/1471-2172-14-34; Gottenberg JE, Ravaud P. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry. Ann Rheum Dis. 2012;71:1815-9. doi:10.1136/annrheumdis-2011-201109; Nü βlein HG, Alten R, Galeazzi M, et al. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskelet Disord. 201516:176. doi:10.1186/s12891-015-0636-9; Kubo S, Nakayamada S, Nakano K, et al. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. Ann Rheum Dis. 2015;0:1-7. doi:10.1136/annrheumdis-2015-207784; Hanaoka R, Kasama T, Muramatsu M, et al. A novel mechanism for the regulation of IFN- γ inducible protein-10 expression in rheumatoid arthritis. Arthritis Res Ther. 2003;5:R74- R81. doi:10.1186/ar616; Ichikawa T, Kageyama T, Kobayashi H, et al. Etanercept treatment reduces the serum levels of interleukin-15 and interferon-gamma inducible protein-10 in patients with rheumatoid arthritis. Rheumatol Int. 2010;30:725-30. doi:10.1007/s00296-009-1356-y; Kageyama Y, Torikai E, Nagano A. Anti-tumor necrosis factoralpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis. Rheumatol Int. 2007;27:467-72. doi:10.1007/s00296-006-0241-1; Авдеева АС, Новиков АА, Александрова ЕН и др. Значение показателей цитокинового профиля при оценке эффективности терапии моноклональными антителами к рецепторам интерлейкина-6 при ревматоидном артрите. Клиническая медицина. 2014;92(1):28-34 [Avdeeva AS, Novikov AA, Aleksandrova EN, et al. The importance of cytokine profile characteristics for evaluating the therapeutic effectiveness of monoclonal antibodies against IL-6 receptors in patients with rheumatoid arthritis. Klinicheskaya Meditsina. 2014;92(1):28-34 (In Russ.)].; Johansen JS, Stoltenberg M, Hansen M, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford). 1999;38(7):618-26. doi:10.1093/rheumatology/38.7.618; Matsumoto T, Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis: Correlations between clinical and laboratory parameters. Clin Exp Rheumatol. 2001;19(6):655-60.; Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid Arthritis Classification Criteria. Arthritis Rheum. 2010;62:2569-81. doi:10.1002/art.27584; Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8. doi:10.1002/art.1780380107; Aletaha D, Nell V, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):796-806. doi:10.1186/ar1740; Pincus T, Swearingen C, Wolfe F. Toward a multy-dimensional Health Assessment Questionnaire (MDHAQ) – assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum. 1999;42:2220-30. doi:10.1002/1529-0131(199910)42:103.0.CO;2-5; Fransen J, Stucki G, van Reil PLCM. Rheumatoid arthritis measures. Arthritis Rheum. 2003;49:214-24. doi:10.1002/art.11407; Marti L, Golmia R. Alterations in cytokine profile and dendritic cells subsets in peripheral blood of rheumatoid arthritis patients before and after biologic therapy. Ann N Y Acad Sci. 2009 Sep;1173:334-42. doi:10.1111/j.1749-6632.2009.04740.x; Murakami M, Matsutani T, Sekiguchi M, et al. SAT0121 Changes in cytokine profiles in rheumatoid arthritis patients during abatacept treatment. Ann Rheum Dis. 2013;72:A622. doi:10.1136/annrheumdis-2013-eular.1847; https://rsp.mediar-press.net/rsp/article/view/2409

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2409
https://doi.org/10.14412/1995-4484-2017-368-375

المؤلفون: G. V. Lukina, Y. A. Sigidin, E. S. Posdnyakova, E. L. Luchihina, D. E. Karateev, E. L. Nasonov, Г. В. Лукина, Я. А. Сигидин, Е. С. Позднякова, Е. Л. Лучихина, Д. Е. Каратеев, Е. Л. Насонов

المصدر: Rheumatology Science and Practice; Vol 45, No 4 (2007); 60-65 ; Научно-практическая ревматология; Vol 45, No 4 (2007); 60-65 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20074

مصطلحات موضوعية: инфликсимаб, anticytokine therapy, infliximab, антицитокиновая терапия

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2189/1409; Maini R.N., St Clair E.W., Breedveld F. et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet , 1999, 354, 932-939.; Lipsky P., Heijde van der D., St Clair E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. New Engl.J.Med., 2000, 343, 1594-1602.; Furst D., Keystone E., Breedveld F. et al. Updated consensus statement on tumour necrosis factor blocking agent for the treatment of rheumatoid arthritis and other rheumatic diseases. Ann.Rheum. Dis., 2001, 60, suppl.III, iii 2-5.; Ostergaard M., Unkerskov J., Krogh N.S. et al. Poor remission rates but long drug survival in rheumatoid arthritis patients treаted with infliximab or etanercept – results from the nationwide danish “danbio” database. Ann.Rheum.Dis., 2005, 64, 59- 60.; Quinn M.A., Conaghan P.G., Greenstein A. et al. Sustained response in early poor prognosis RA after withdrawal of infliximab therapy. Arthr.Rheum., 2002, 46, 3416.; Breedveld F.C., Emery P., Keystone E. et al. Infliximab in active early rheumatoid arthritis. Ann. Rheum.Dis., 2004, 63, 149-155.; Van der Bijl A.E., Goekoop-Ruiterman Y.P., Breedveld F.C. et al. Many early rheumatoid arthritis patients with a good clinical response to infliximab can discontinue anti-TNF-alpha therapy without relapse. Ann.Rheum.Dis., 2005, 64, suppl.III, 59.; De Vries-Bouwsta J.K., Goekoop-Ruiterman Y., van Zeben D. et al. A comparison of clinical and radiological outcomes of four treatment strategies for early rheumatoid arthritis: results of the BeST trial. Ann.Rheum.Dis., 2004, 63, suppl.1, S58; Bathon J., Martin R.W., Fleischmann R.M. et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N.Engl. J.Med., 2000, 343, 1586-1593.; Genovese M.C., Martin R.W., Fleishmann R.M. et al. Etanercept (Enbrel) in early erosive rheumatoid arthritis (Era Trial): 5-year clinical and radiographic data. Arthr.Rheum., 2003, 48, suppl., S122.; Keystone E., Kavanaugh A., Fischkoff S. Response to adalimumab in patients with early versus late rheumatoid arthritis (RA). Ann.Rheum.Dis., 2003, 62, suppl. 1., 170.; Smolen J.S., Han C., Bala M. et al. Infliximab consistently induces clinical remission in patients with early active rheumatoid arthritis regardless of remission criteria. Arthr.Rheum., 2005, 52 suppl., S139.; Van der Heijde D., Emery P., Keystone E.C. et al. Effect of Infliximab and methotrexate on radiographic progression in patients with early rheumatoid arthritis. Arthr.Rheum., 2005, 52 suppl, S139- 140.; Lequerre T., Vittecog O., Kemmer N. et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis. J.Rheumatol., 2006, 33, 1307-1314.; https://rsp.mediar-press.net/rsp/article/view/2189

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2189
https://doi.org/10.14412/1995-4484-2007-60-65

المؤلفون: G. V. Lukina, Ya. A. Sigidin, Г. В. Лукина, Я. А. Сигидин

المصدر: Rheumatology Science and Practice; Vol 53, No 2 (2015); 200-204 ; Научно-практическая ревматология; Vol 53, No 2 (2015); 200-204 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20152

مصطلحات موضوعية: ревматические заболевания, adverse events, rheumatic diseases, безопасность, нежелательные реакции

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2076/1307; Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861–74. doi:10.1016/S0140-6736(07)60784-3; Насонов ЕЛ. Перспективы лечения ревматических заболеваний в начале 21 века. Терапевтический архив. 2011;(5):5–9. [Nasonov EL. Prospects for treatment of rheumatic diseases in the early 21st century. Terapevticheskii arkhiv. 2011;(5):5–9. (In Russ.)].; Feldman M, Maini RN. Role of cytokines in rheumatoid arthritis: an education in pathophysiology ant therapeutics. Immunol Rev. 2008;223:7–19. doi:10.1111/j.1600-065X.2008.00626.x; Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol. 2010;10:308–15. doi:10.1016/j.coph.2010.01.005; Насонов ЕЛ. Место голимумаба при ревматоидном артрите. Научно-практическая ревматология. 2012;51(Прил. 3):2–10. [Nasonov EL. Place of golimumab in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;51(Прил. 3):2–10. (In Russ.)].; Эрдес ШФ. Применение голимумаба при анкилозирующем спондилите. Научно-практическая ревматология. 2012;51(Прил. 3):11–6. [Erdes ShF. The use of golimumab in ankylosing spondylitis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;51(Прил. 3):11–6. (In Russ.)].; Коротаева ТВ. Результаты оценки эффективности и безопасности голимумаба — нового ингибитора фактора некроза опухоли альфа в лечении псориатического артрита. Научно-практическая ревматология. 2012;51(Прил. 3):17–22. [Korotaeva TV. The results of evaluation of the effectiveness and safety of golimumab – new inhibitor of tumor necrosis factor Alfa treatment of psoriatic arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;51(Прил. 3):17–22. (In Russ.)].; Beevor CP, Hull R, Thomas A, et al. Anti TNFa therapy reduce emergency health services usage. Ann Rheum Dis. 2006;65 Suppl II:176.; Gomez-Reino JJ, Dasgupta B, Haugeberg G, et al. Mortality rate is reduced in RA patients treated with TNF antagonists. Data from Biobadaser. Ann Rheum Dis. 2006;65 Suppl II:318.; Abbott Laboratories. Humira (adalimumab) [highlights of prescribing information]. Last revised September 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/12505 7s232lbl.pdf (accessed 17 Apr 2013).; UCB Inc. Cimzia (certolizumab) [highlights of prescribing information]. Last revised November 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/12516 0s189lbl.pdf (accessed 17 Apr 2013).; Amgen Wyeth, manufactured by Immunex. Enbrel (etanercept) [highlights of prescribing information]. Last revised December 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103795s5507lbl.pdf (accessed 17 Apr 2013).; Janssen Biotech, Inc. Remicade (infliximab) [highlights of prescribing information]. Last revised March 2013. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5345lbl.pdf (accessed 17 Apr 2013).; Zhou H, Xu Z, Rahman MU, et al. Exposure-efficacy assessment of golimumab in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2006;65:514.; Smolen J, Kay J, Doyle MK, et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody. Ann Rheum Dis. 2008;67 Suppl II:50–1.; Keystone E, Genovese MC, Klareskog L, et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody. Ann Rheum Dis. 2009;68:789–96. doi:10.1136/ard.2008.099010; Kay J, Fleischmann R, Keystone E, et al. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. Published Online First: doi:10.1136/ annrheumdis-2013-204195; Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis wth tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122–7. doi:10.1002/art.11137; Насонов ЕЛ, Козлов РС, Якушин СБ. Инфекционные осложнения терапии блокаторами фактора некроза опухоли: предупрежден – значит вооружен. Клиническая микробиология и антимикробная химиотерапия. ;(4):1–11. [Nasonov EL, Kozlov RS, Yakushin SB. Infectious complications of therapy of tumor necrosis factor blockers: forewarned – is forearmed. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2006;(4):1–11. (In Russ.)].; Furst DE, Keystone EC, Fleischmann R, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis. 2010;69 Suppl:i2–29. doi:10.1136/ard.2009.123885; Cellestis. QuantiFERON-TB Gold clinicians guide and QuantiFERON-TB Gold In-Tube method package insert. Available from: www.cellestis.com; Oxford Immunotec. T-SPOT.TB. Available from: http://www.oxford immunotec.com/T-SPOT_International; Hsia E, Cush J, Eric L, et al. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in phase III clinical trials. Arthritis Care Res. 2013 Feb;65(2):309–13. doi:10.1002/acr.21788; Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al.; on behalf of the BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52:1766–72. doi:10.1002/art.21043; Available from: www.who.int/tb/country/data/download/en/index.html; Janssen Biotech, Inc. Simponi (golimumab) [highlights of prescribing information]. Last revised November 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125289s070lbl.pdf (accessed 17 Apr 2013).; Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;2:CD008794. doi:10.1002/14651858.CD008794.pub2; Kay J, Rahman MU. Golimumab: A novel human anti-TNFalpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evid. 2010;4:159–70.; https://rsp.mediar-press.net/rsp/article/view/2076

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2076
https://doi.org/10.14412/1995-4484-2015-200-204

المؤلفون: Yakov Aleksandrovich Sigidin, G V Lukina, Я. А. Сигидин, Г. В. Лукина

المصدر: Rheumatology Science and Practice; Vol 51, No 5 (2013); 476-480 ; Научно-практическая ревматология; Vol 51, No 5 (2013); 476-480 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-5

مصطلحات موضوعية: генно-инженерные биологические препараты, cytokines, genetically engineered biological agents, цитокины

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1332/991; Насонов ЕЛ. Перспективы развития ревматологии в XXI веке. Русский медицинский журнал. 2001;(23):1031–2. [Nasonov EL. Perspektivy razvitiya revmatologii v XXI veke. Russkiy meditsinskiy zhurnal. 2001;(23):1031–2.] Насонов ЕЛ. Лечение ревматоидного артрита: современное состояние проблемы. Русский медицинский журнал. 2006;(8):573–7. [Nasonov EL. Lechenie revmatoidnogo artrita: sovremennoe sostoyanie problemy. Russkiy meditsinskiy zhurnal. 2006;(8):573–7.] Насонова ВА. Ревматология: взгляд в XXI век. Вестник РАМН. 2003;(7):3–6. [Nasonova VA. Rheumatology: an outlook for the 21st century. Vestnik RAMN. 2003;(7):3–6.] Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. 549 с. [Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita. Moscow: IMA-PRESS; 2013. 549 p.] Сигидин ЯА, Лукина ГВ. Биологическая терапия в ревматологии. 2-е изд. Москва: Практическая медицина; 2009. 301 с. [Sigidin YaA, Lukina GV. Biologicheskaya terapiya v revmatologii. 2-e izd. Moscow: Prakticheskaya meditsina; 2009. 301 p.] Kuiper S, Joosten LA, Bendele AM et al. Different roles of tumor necrosis factor alpha and interleukin 1 in murine streprococcal cell wall arthritis. Cytokine. 1998;10(9):690–702. Lindqvist E, Eberhardt K, Bendtzen K et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis. 2005;64(2):196–201. DOI: http://dx.doi.org/10.1136%2Fard.2003.019992. Epub 2004 Sep 30. Den Broeder AA, de Long E, Franssen MJ et al. Observational study on efficacy, safety and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis. 2006;65(6):760–2. DOI: http://dx.doi.org/10.1136%2Fard.2004.033662. Epub 2005 Nov 3. Singh JA, Christensen R, Wells G et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews (Review). Cochrane Database Syst Rev. 2009;(4):CD007848. DOI:10.1002/14651858.CD007848.pub2. Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease. Arthritis Res Ther. 2011;13(3):R91. DOI:10.1186/ar3366. Braun-Moscovici Y, Markovitz D, Zinder O et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrоsis factor-α therapy in patients with rheumatoid arthritis. J Rheumatol. 2006;33(3):497–500. De Rycke L, Verhelst X, Kruithof E et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis. 2005;64(2):299–302. DOI: http://dx.doi.org/10.1136%2Fard.2004.023523. Epub 2004 May 27. Ravindran J, Shenker N, Bhalla AK. Case report: response in proteinuria due to AA amyloidosis but not Felty’s syndrome in a patient with rheumatoid arthritis treated with TNF-α blockade. Rheumatology (Oxford). 2004;43(5):669–72. Никишина ИП, Родионовская СР. Терапия рефрактерных вариантов ювенильного артрита. Consilium medicum. 2006;2 (приложение педиатрия):85–9. [Nikishina IP, Rodionovskaya SR. Terapiya refrakternykh variantov yuvenil'nogo artrita. Consilium medicum. 2006;2 (prilozhenie pediatriya):85–9.] Вraun J, Landewe R, Hermann K-G et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab. Arthritis Rheum. 2006;54(5):1646–52. Van der Heijde D, Pangan AL, Schiff MH et al. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis. 2008;67(9):1218–21. DOI: http://dx.doi.org/10.1136%2Fard.2007.082529. Epub 2007 Dec 4. Davis JC, van der Heijde D, Braun J et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230–6. DOI: http://dx.doi.org/10.1002%2Fart.11325. Baeten D, Kruithof E, Breban M. Spondylarthritis in the absence of B lymphocytes. Arthritis Rheum. 2008;58(3):730–3. DOI:10.1002/art.23266. Song IH, Heldmann F, Rudwaleit M. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann. Rheum Dis. 2011;70(6):1108–10. DOI:10.1136/ard.2010.145946. Epub 2011 Mar 17. Lekpa FK, Farrenq V, Canouï-Poitrine F et al. Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. Joint Bone Spine. 2012;79(1):47–50. DOI:10.1016/j.jbspin.2011.02.018. Epub 2011 Apr 15. Zoul J, Zhang Y, Thiel A et al. Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. Rheumatology (Oxford). 2003;42(7):846–55. Epub 2003 Feb 28. Wanders A, Heijde D, Landewe R et al. Nonsteroidal non-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756–65. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol. 1996;14:397–440. Kinne RW, Brauer R, Stuhlmuller B et al. Macrophages in rheumatoid arthritis. Arthritis Res. 2000;2(3):189–202. Epub 2000 Apr 12. DOI: http://dx.doi.org/10.1186%2Far2333. Gracie JA, Leung BP, McInnes IB. Novel pathways that regulate tumor necrosis factor-alpha production in rheumatoid arthritis. Curr Opin Rheumatol. 2002;14(3):270–5. DOI: http://dx.doi.org/10.1097%2F00002281-200205000-00013. McInnes IB, Leung BP, Liew FY. Cell-cell interactions in synovitis. Interactions between T lymphocytes and synovial cells. Arthritis Res. 2000;2(5):374–8. Epub 2000 Jul 18. Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: Фокус на ритуксимаб. Москва: ИМА-ПРЕСС; 2012. 344 с. [Nasonov EL, editor. Anti-V-kletochnaya terapiya v revmatologii: Fokus na rituksimab. Moscow: IMA-PRESS; 2012. 344 p.] Maneiro RJ, Salgado E, Carmona L et al. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. Semin Arthritis Rheum. 2013;43(1):9–17. DOI:10.1016/j.semarthrit.2012.11.007. Epub 2013 Jan 2. Chatzidionysiou K, Lie E, Nasonov E et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Аnn Rheum Dis. 2011;70(9):1575–80. DOI:10.1136/ard.2010.148759. Epub 2011 May 12. Kobayakawa T, Hayashi M, Kanamono T et al. Correlation between abatacept and rheumatoid factor. Can rheumatoid factor be a predictive factor for abatacept? Arthritis Rheum. 2012;64 suppl 10:2314. Brennan FM, Chantry D, Jackson A et al. Inhibitory effect of TNF antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;2(8657):244–7. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002;2(5):364–71. DOI: http://dx.doi.org/10.1038%2Fnri802. Elliot MJ, Maini RN, Feldmann M et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor  (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344(8930):1105–11. Emery P, Tony H, Kremer J et al. Long-term efficacy of tocilizumab in RA patients who have inadequate response to anti-TNF therapy. Ann Rheum Dis. 2011;70 suppl 3:615. Lovell D, Giannini E, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. New Engl J Med. 2000;342(11):763–9. DOI: http://dx.doi.org/10.1056%2FNEJM200003163421103. Giannini EH, Ilowite NT, Lovell DJ et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(11):3259–64. DOI:10.1002/art.27682. Yokota S, Imagawa T, Mori M et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998–1006. DOI:10.1016/S0140-6736(08)60454-7. Ruperto N, Lovell DJ, Quartier P et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–91. DOI:10.1016/S0140-6736(08)60998-8. Epub 2008 Jul 14. Sherer Y, Gorstein A, Fritzler MJ et al. Autoantibody explosion in systemic lupus erythematosus: More than 100 different antibodies found in SLE patients. Semin Arthritis Rheum. 2004;34(2):501–37. Petry M, Furie R, Merrill J et al. Six-year eхperience with belimumab in patients with SLE. Ann Rheum Dis. 2011;70 suppl 3:314. Navarra SV, Guzman RM, Gallacher AE et al. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9676):721–31. DOI:10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4. Furie R, Petri M., Zamani O et al. BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–30. DOI:10.1002/art.30613. Tokunaga M, Saito K, Kawabata D et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66(4):470–5. DOI: http://dx.doi.org/10.1136%2Fard.2006.057885. Epub 2006 Nov 15. Merrill JT, Burgos-Vargas R, Westhovens R et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, Phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(10):3077–87. DOI:10.1002/art.27601. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012;64(11):3660–5. DOI:10.1002/art.34624. Zhu L-J, Yang X, Yu X-Q. Anti-TNF-α therapies in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:465898. DOI:10.1155/2010/465898. Epub 2010 Jun 22. Singh JA, Wells G, Christensen R et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011 ;(2):CD008794. DOI:10.1002/14651858.CD008794.pub2.; https://rsp.mediar-press.net/rsp/article/view/1332

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1332
https://doi.org/10.14412/1995-4484-2013-1537

المؤلفون: Galina Viktorovna Lukina, Ya A Sigidin, Г. В. Лукина, Я. А. Сигидин

المصدر: Modern Rheumatology Journal; Том 6, № 2 (2012); 44-49 ; Современная ревматология; Том 6, № 2 (2012); 44-49 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2012-2

مصطلحات موضوعية: цертолизумаб пегол, certolizumab pegol

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/412/390; Beevor C.P., Hull R., Thomas A. et al. Anti TNFa therapy reduce emergency health services usage. Ann Rheum Dis 2006; 65(Suppl. II): 176. Никишина И.П., Родионовская С.Р. Терапия рефрактерных вариантов ювенильного артрита. Cons med 2006 (прил. Педиатрия); 2: 85-9. Finzel S., Rech J., Schmidt S. et al. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of erosion. Ann Rheum Dis 2011; 70: 1587-93. Fossati G., Nesbitt A. Certolizumab pegol has a different profile from the other anti-TNFs, including golimumab, in a variety of in vitro assays. Ann Rheum Dis 2010; 69(Suppl. 3): 324. Palframan R., Ayrey M., Moore A. et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Meth 2009; 348: 36-41. Schrelber S., Khalig-Kaaremi M., Lawrance I. et al. Certolizumab pegol, a pegylated Fab’ fragment of a humanised anti-TNF monoclonal antibody, is safe and effective in the maintenance of response and remission following induction in active Crohn’s disease: a phase III study. Ann Rheum Dis 2006; 65(Suppl. II): 500. Насонов Е.Л., Амирджанова В.Н. Новые аспекты фармакотерапии ревматоидного артрита: фокус на цертолизумаб пе-гол. Науч.-практ. ревматол. 2011; 1: 40-9. Fleischmann R., Vencovsky J., van Vollenhoven R. et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68: 805-11. Keystone E.C., Curtis J.R., Fleischmann R.M. et al. Rapid improvement in signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: Post-hoc analysis of randomized controlled trial. J Rheumatol. First release March 1, 2011; doi:10.3899/jrheum.100935. Keystone E., van der Heide D., Mason D. et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Arthr Rheum 2008; 58: 3319-29. Smolen J., Landewe R.B., Mease P. et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804. Weinblatt M., Fleischmann R., van Vollenhoven R. et al. Certolizumab pegol as monotherapy or with concomitant DMARDs in patients with active rheumatoid arthritis (RA) with or without prior TNF inhibitor use: analysis of the realistic 12-week phase III randomised controlled study. Ann Rheum Dis 2011; 70(Suppl. 3): 414. Smolen J., Emery P., Ferraccioli G. et al. Efficacy and safety of certolizumab pegol after incomplete response to DMARDs in RA patients with low moderate disease activity: Results from CERTAIN, a phase IIIb study. Ann Rheum Dis 2011; 70(Suppl. 3): 259. Gallego-Galisteo M., Villa-Rubio A., Alegre-del Rey E. et al. Indirect comparison of biological treatment in refractory rheumatoid arthritis. J Clin Pharm Ther doi:10.1111/j.1365—2710.2011.01292.x Mease P.G., Keystone E., Mason D. et al. Safety of сertolizumab pegol with methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2008; 67 (Suppl. II): 324-5. Singh J.A., Wells G., Christensen R. et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews, 2011; Is. 2. Wolf D., Mahadevan U. Certolizumab Pegol use in pregnancy: low levels detected in cord blood. Arthr Rheum 2010; 62 (Suppl. 10): 299.; https://mrj.ima-press.net/mrj/article/view/412

الاتاحة: https://mrj.ima-press.net/mrj/article/view/412
https://doi.org/10.14412/1996-7012-2012-727

المؤلفون: G V Lukina, Ya A Sigidin, E S Pozdnyakova, E N Aleksandrova, A A Novikov, A V Smirnov, S I Glukhova, E L Nasonov, Г. В. Лукина, Я. А. Сигидин, Е. С. Позднякова, Елена Николаевна Александрова, А. А. Новиков, А. В. Смирнов, С. И. Глухова, Евгений Львович Насонов

المصدر: Modern Rheumatology Journal; Том 6, № 3 (2012); 37-43 ; Современная ревматология; Том 6, № 3 (2012); 37-43 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2012-3

مصطلحات موضوعية: Российский регистр биологической терапии ревматоидного артита, genetically engineered biological agents, infliximab, Russian biological rheumatoid arthritis therapy registry, генно-инженерные биологические препараты, инфликсимаб

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/429/407; https://mrj.ima-press.net/mrj/article/view/429

الاتاحة: https://mrj.ima-press.net/mrj/article/view/429
https://doi.org/10.14412/1996-7012-2012-744

المؤلفون: A. A. Novikov, E. N. Aleksandrova, T. V. Popkova, O. G. Lineva, A. S. Avdeyeva, D. S. Novikova, G. Kh. Kuzikyants, G. V. Lukina, Ya. A. Sigidin, A. V. Karaulov, S. N. Bykovskaya, E. L. Nasonov, А. А. Новиков, Елена Николаевна Александрова, Т. В. Попкова, О. Г. Линева, А. С. Авдеева, Д. С. Новикова, Г. Х. Кузикянц, Г. В. Лукина, Я. А. Сигидин, А. В. Караулов, С. Н. Быковская, Е. Л. Насонов

المصدر: Rheumatology Science and Practice; Vol 49, No 5 (2011); 51-57 ; Научно-практическая ревматология; Vol 49, No 5 (2011); 51-57 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2011-3

مصطلحات موضوعية: мультиплексный анализ, rituximab, cytokines, multiplex analysis, ритуксимаб, цитокины

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1293/1034; Browning J.L. B cell move to centre stage: novel opportunities for autoimmune disease treatment. Nature Rev 2006;5:564-76. Насонов Е.Л. Перспективы применения моноклональных антител к В-лимфоцитам (ритуксимаб) при ревматоидном артрите. Клин фармакол тер 2006;1-5:55-8. Do rner T. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol 2006;77:3-11. Wilk E., Witte T., Marquardt N. et al. Depletion of functionally active CD20- T cells by rituximab treatment. Arthr Rheum 2009;12(60):3563-71. Yamamoto A., Sato К., Miyoshi F. et al. Analisis of cytokine production patterns of peripheriel blood mononuclear cells from a rheumatoid arthritis patient successfully treated witch rituximab. Mod Rheumatol 2010;2:183-7. Brennan F., McInnes I. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118(11):3537-45. Bansard C., Lequerre T., Daveau M. еt al. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predictedRheumatology (Oxford) 2009;48(9): 1021-8. Kingsmore S. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat Rev Drug Discov 2006;5(4):310-20. Олюнин Ю.А. Оценка эффективности терапии ревматоидного артрита. Международные индексы оценки активности, функционального статуса и качества жизни больных ревматическими заболеваниями. М., 2007;3-12. Blom M., Wenink M., Huijbens R. et al. Altered Circulating Cytokine Pattern after Administration of Rituximab is Correlated with Response to Therapy in Rheumatoid Arthritis. Arthr Rheum 2008;58(19):450. Fabre S., Guisset C., Tatem L. et al. Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Clin Exp Immunol 2009;155(3):395-402. Thurling R.M., Boumans M.J.H., Vos K. et al. Early changes in serum levels of cytokines and chemokines are predictive of the response to Rituximab treatment in rheumatoid arthritis. Arthr Rheum 2009;60(Suppl.):630; https://rsp.mediar-press.net/rsp/article/view/1293

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1293
https://doi.org/10.14412/1995-4484-2011-1461

المؤلفون: Evgeniy L'vovich Nasonov, G V Lukina, Ya A Sigidin, Evgeny Lvovich Nasonov, Евгений Львович Насонов, Г. В. Лукина, Я. А. Сигидин

المصدر: Rheumatology Science and Practice; Vol 49, No 1 (2011); 16-20 ; Научно-практическая ревматология; Vol 49, No 1 (2011); 16-20 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2011-1

مصطلحات موضوعية: терапия ревматоидного артрита, methorexate, leflunomide, therapy for rheumatoid arthritis, метотрексат, лефлуномид

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/995/686; Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; 290-331. Klareskog L., Cartina A.I., Paget S. Rheumatoid arthritis. Lancet 2009; 373: 659-72. Smolen J.S., Aletaha D., Bijsma J.W.J. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7. Smolen J.S., Landewe R., Breedveld F.C. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75. Ревматология. Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010. Насонов Е.Л. Фармакотерапия ревматоидного артрита - взгляд в 21 век. Клин. мед. 2005; 6: 8-12. Насонов Е.Л. Фармакотерапия ревматоидного артрита в эру генно-инженерных биологических препаратов. Тер. арх. 2007; 5: 5-8. Решетняк Д.В., Насонов Е.Л. Новые направления лечения ревматоидного артрита: механизмы действия и клиническая эффективность лефлуномида. Науч.- практич. ревматол. 2001; 5: 39-45. Gaujoux-Viala C., Smolen J.S., Landewe R. et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systemic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010 (on-line). Чичасова Н.В., Насонов Е.Л. Лефлуномид в лечении ревматических заболеваний. М.: МегаПро, 2010; 110 с. Jones P.B.B., White D.H.N. Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis. Open Access Rheumatol Res Rev 2010; 2: 53-71. Saag K.G., Teng G.G., Patkar N.M. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumat- ic drugs in rheumatoid arthritis. Arthr Rheum 2008; 59: 762-84. Насонов Е.Л. Перспективы комбинированной терапии ревматоидного артрита - лефлуномид и инфликсимаб. Рус. мед. журн. 2008; 16(10): 633-7. Strangfeld A., Hierse F., Kekow J. et al. Comparative effectiveness of tumor necrosis factor a inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 2009; 68: 1856-62. Насонов Е.Л. Применение ритуксимаба при ревматоидном артрите: 2010. Науч.-практич. ревматол. 2010; 4(Прил. 1) : 10-40. Vital Е., Dass S., Rawstron A.C., Emery P. Combination rituximab and leflunomide produces lasting responses in rheumatoid arthritis. Ann Rheum Dis 2008; 67 (Suppl. II) : 90. Henes J., Schedel J., Kanz L. et al. Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis. Rheumatol Int 2010; 30: 709-12. Wendler J., Soerensen H.,Tony H. et al. Effectiveness and safety of rituximab (RTX)-monotherapy compared to RTX-combination therapy with methotrexate (MTX) and leflunomide (LEF) in the German RTX treatment of active rheumatoid arthritis (RA) in daily practice trial. Ann Rheum Dis 2009; 68(Suppl. 3): 76. Narvaez J., Torne C.D., Ruiz J.M. et al. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. Arthr Rheum 2010; 62(Suppl.): S748 [1796]. Gabay C., Chatzidionysiou K., Nasonov E. et al. Effectiveness of different DMARD co-therapy in Rituximab-treated rheumatoid arthritis (RA) patients - results of a one-year follow up study from the CERERRA collaboration. Ann Rheum Dis 2010; 69(Suppl. 3): 68.; https://rsp.mediar-press.net/rsp/article/view/995

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/995
https://doi.org/10.14412/1995-4484-2011-862

المؤلفون: V N Amirdzhanova, Elena Yur'evna Kaygorodtseva, D V Goryachev, G V Lukina, E S Pozdnyakova, Ya A Sigidin, E L Nasonov, Elena Yuryevna Kaigorodtseva, Г. В. Лукина, Е. С. Позднякова, Я. А. Сигидин, Евгений Львович Насонов

المصدر: Rheumatology Science and Practice; Vol 48, No 6 (2010); 23-30 ; Научно-практическая ревматология; Vol 48, No 6 (2010); 23-30 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2010-6

مصطلحات موضوعية: регистр Инфликсимаба, patients' functional state, registry of Infliximab, функциональное состояние больных

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/952/644; Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; 720 с. Сигидин Я.А., Лукина Г.В. Биологическая терапия в ревматологии. 2-е изд., доп. М.: Практическая медицина, 2009; 41-5. Насонов Е.Л. Инновационные технологии в диагностике и лечении ревматических заболеваний (лекции цикла повышения квалификации врачей). М.: Изд-во АРР, 2009; 9,18. Maini R.N., Breedveld F.C., Kalden J.R. for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concominant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthr Rheum 2004; 50: 1051-65. Kavanaugh A., Han C., Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 849-55. Han C., Smolen J., Kavanaugh A. et al. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthr Res Ther 2007; 9: R103. Durez P., Nzeusseu Toukap A., Lauwerys B.R. A randomized comparative study of short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite metotrexate treatment. Ann Rheum Dis 2004; 63: 1069-74. Lipsky P.E., van der Heijde D.M., St Clair E.W. for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concominant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602. Амирджанова В.Н., Кайгородцева Е.Ю., Савенкова Н.А., Насонов Е.Л. Качество жизни как критерий эффективности терапии базисными противовоспалительными и генно-инженерными биологическими препаратами: результаты международных и российских исследований. Науч.-практич. ревматол. 2009; 2: 54-78. Приказ МЗ СР РФ № 315н от 4 мая 2010 г. «Об утверждении Порядка оказания медицинской помощи больным с ревматическими заболеваниями» (Прил. 8). Насонов Е.Л., Лукина Г.В., Сигидин Я.А. и др. Результаты Российского регистра применения препарата Инфликсимаб при ревматоидном артрите: Тезисы. М., 2009. Лукина Г.В., Сигидин Я.А., Насонов Е.Л. Применение Инфликсимаба у больных ревматоидным артритом в клинической практике (по данным Российского регистра). Тер. арх. 2009; 81(8): 65-9. Felson D.T., Anderson J.J., Boers M. et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthr Rheum 1993; 36: 729-40. Prevoo M.L., van't Hof M.A., Kuper H.H. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthr Rheum 1995; 38: 44-8. Fries J.F., Spitz P.W., Kraines R.G., Holman H.R. Measurement of patient outcome in arthritis. Arthr Rheum 1980; 23: 137-45. Kosinski M., Zhao S.Z., Dedhiya S. et al. Determining minimally important changes in general and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthr Rheum 2000; 43(7): 1478-87. Лечение ревматоидного артрита. Клинические рекомендации. Под ред. Е.Л. Насонова. М.: Алмаз, 2006; 90-1. Международные индексы оценки активности, функционального статуса и качества жизни больных ревматическими заболеваниями. М.: Ассоциация ревматологов России, 2007; 28 c. Waladkhani A.R. Conducting Clinical Trials. A theoretical and practical guide. S. 1., 2008.; https://rsp.mediar-press.net/rsp/article/view/952

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/952
https://doi.org/10.14412/1995-4484-2010-819

المؤلفون: G V Lukina, E L Nasonov, Ya A Sigidin, K Kh Kuzikyants, L. L. Bazevich, T I Zlobnna, R G Kamalova, L A Knyazeva, V I Mazurov, L V Men'shikova, A E Sizikov, E A Smirnova, N A Fofonova, T V Shabalina, L M Shkil', N V Yudina, S S Yakushin, Г. В. Лукина, Евгений Львович Насонов, Я. А. Сигидин, Л. А. Князева, В. И. Мазуров

المصدر: Rheumatology Science and Practice; Vol 46, No 1s (2008); 11-14 ; Научно-практическая ревматология; Vol 46, No 1s (2008); 11-14 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2008-1s

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/286/140; https://rsp.mediar-press.net/rsp/article/view/286

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/286
https://doi.org/10.14412/1995-4484-2008-2

المؤلفون: I R Kolosova, E R Polosukhina, L Yu Baryshnikov, G V Lukina, Ya. A. Sigidin, Г. В. Лукина, Я. А. Сигидин

المصدر: Rheumatology Science and Practice; Vol 40, No 2 (2002); 37 ; Научно-практическая ревматология; Vol 40, No 2 (2002); 37 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2002-2

Relation: https://rsp.mediar-press.net/rsp/article/view/447

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/447
https://doi.org/10.14412/1995-4484-2002-104

المؤلفون: G V Lukina, Y A Sigidin, Г. В. Лукина, Я. А. Сигидин

المصدر: Rheumatology Science and Practice; Vol 39, No 2 (2001); 51-53 ; Научно-практическая ревматология; Vol 39, No 2 (2001); 51-53 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2001-2

مصطلحات موضوعية: остеоартроз, chondroprotector, osteoarthritis, хондропротектор

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/538/246; Гроппа Л.Г., Мьшзату П., Карасава М., Ключникова Л., Балан И. Корецкая В., Гаврнлащснко Л Эффективность алфлутопа у больных деформирующим артрозом. Клиннч. рсвматол., 1995. 3. 20-22. Коршунов Н.И., Баранова З.Я., Парусова Н.М., Полуночев Г. Б., Чучканов Ф.А. Алфлутоп в лечении больных остеоартрозом. Росс, ревматол., 199S, 2. 26-31. Лукина Г.В., Снгидин Я.А. Опыт применения препарата альфлутоп в лечении остеоартроза. Клинич. ревматол,, 1996, 4. 40-43. Mankin H.S., Brandi K.D. Biochemistry and metabolism of cartilage in osteoarthritis. Osteoarthritis Diagnosis and Management, ed. by Moskowia RAV., Hawell D.S., Goldberg V.M. et al. Philadelphia. W.B. Saunders. 1992, 109-154.; https://rsp.mediar-press.net/rsp/article/view/538

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/538
https://doi.org/10.14412/1995-4484-2001-400